pharma · Rheumatoid Arthritis · Warm Antibody Autoimmune Hemolytic Anemia · RIGL
RIGEL PHARMACEUTICALS
RIGEL PHARMACEUTICALS INC
Rigel Pharmaceuticals is a pharma organization headquartered in South San Francisco, USA. It trades on NYSE under ticker RIGL. Primary therapeutic focus areas include Rheumatoid Arthritis, Warm Antibody Autoimmune Hemoly
1180 Veterans Blvd, South San Francisco, CA 94080, US HQ
1996 Founded
286 Employees
Public company Type
RIGL · NYSE Ticker
Company details
- Status
- Public
- HQ
- 1180 Veterans Blvd, South San Francisco, CA 94080, US
- Founded
- 1996
- Employees
- 286
- Programs
- 36
- Drugs
- 26
- Patents
- 373
Fostamatinib in combination with chemotherapy (gemcitabine and nab-paclitaxel)
Phase 1 · other · Pancreatic Ductal Adenocarcinoma (PDAC)
Fostamatinib in combination with chemotherapy (gemcitabine and nab-paclitaxel) for Pancreatic Ductal Adenocarcinoma (PDAC) is a Phase 1 program (other) at RIGEL PHARMACEUTICALS INC with 1 ClinicalTrials.gov record(s).
Internal code 810834
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- RIGEL PHARMACEUTICALS INC
- Phase
- Phase 1
- Modality
- other
- Indication
- Pancreatic Ductal Adenocarcinoma (PDAC)
- Status
- active
- Trials
- 1